Market Overview

How Valeant Finally Won Over A Longtime Bear

How Valeant Finally Won Over A Longtime Bear
Related VRX
Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates
TD Ameritrade Traders Adopt Some Old And New Approaches To The Trade War Market In June's IMX

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) fell 20 percent after reporting in-line earnings results.

But the very news that catalyzed a selloff was well-received by one longtime Valeant bear who transformed into a bull Monday.

The Rating

Deutsche Bank analyst Gregg Gilbert upgraded Valeant from Hold to Buy and maintained a $20 price target.

The Thesis

The analyst expressed confidence in the new Valeant leadership team and its strong performance over the last two years.

Valeant returned the core Bausch and Lomb, international and Salix franchises to growth by improving resource allocation and investment, Gilbert said in a Monday note. The strategy drove mid-single-digit growth in 2017, and Deutsche expects five-year expansion from 74 percent of total revenue to 84 percent.

At the same time, the Valeant team reduced debt by $6.7 billion, positioned itself to address the remaining $25 billion maturing in 2020 and resolved enduring legal issues, the analyst said. 

These accomplishments compound improvement in Xifaxan's prospects and justify Valeant's fresh self-assuredness, which was reflected in the release of longer-term revenue guidance, Gilbert said. 

“While challenges remain, most notably the heavy debt load, we believe VRX is doing the right things to strengthen the business, including investing behind core growth franchises, reducing legal liabilities and strengthening the balance sheet,” the analyst said. 

The Deutsche Bank analyst warned that he ex[ects high volatility in the stock, with trading disconnected from fundamentals.

Price Action

Valeant shares were up 4.33 percent at $15.52 at the time of publication Monday morning. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

The Companies That Led 2017's Biotech Rally

Latest Ratings for VRX

Jun 2018TD SecuritiesDowngradesBuyHold
Jun 2018BarclaysUpgradesEqual-WeightOverweight
May 2018MizuhoUpgradesNeutralBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Greg Fraser Gregg GilbertAnalyst Color Upgrades Price Target Top Stories Analyst Ratings Best of Benzinga


Related Articles (VRX)

View Comments and Join the Discussion!

Latest Ratings

XECImperial CapitalDowngrades35.0
SSTIImperial CapitalUpgrades49.0
AVDLoop CapitalUpgrades29.0
FCREYDeutsche BankUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

This Day In Market History: Dow Makes First Post-Financial Crisis High

Should You Limit Your Insurance Claims?